Discovery of Drug Candidates for Specific Human Disease Based on Natural Products of Gut Microbes

Cheng-Yu Wang,Qing-Feng Wen,Qiao-Qiao Wang,Xia Kuang,Chuan Dong,Zi-Xin Deng,Feng-Biao Guo
DOI: https://doi.org/10.3389/fmicb.2022.896740
IF: 5.2
2022-01-01
Frontiers in Microbiology
Abstract:The beneficial metabolites of the microbiome could be used as a tool for screening drugs that have the potential for the therapy of various human diseases. Narrowing down the range of beneficial metabolite candidates in specific diseases was primarily a key step for further validation in model organisms. Herein, we proposed a reasonable hypothesis that the metabolites existing commonly in multiple beneficial (or negatively associated) bacteria might have a high probability of being effective drug candidates for specific diseases. According to this hypothesis, we screened metabolites associated with seven human diseases. For type I diabetes, 45 out of 88 screened metabolites had been reported as potential drugs in the literature. Meanwhile, 18 of these metabolites were specific to type I diabetes. Additionally, metabolite correlation could reflect disease relationships in some sense. Our results have demonstrated the potential of bioinformatics mining gut microbes' metabolites as drug candidates based on reported numerous microbe-disease associations and the Virtual Metabolic Human database. More subtle methods would be developed to ensure more accurate predictions.
What problem does this paper attempt to address?